Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dementia drug developer Axovant nets $337mm in record-breaking IPO

Executive Summary

Axovant Sciences Ltd. (dementia therapeutics) netted $337mm in its initial public offering of 24.2mm shares (including the overallotment) for $15. Affiliates of Visium Asset Management and RA Capital Management agreed to buy 10mm shares. The company had set terms of 17.9mm shares at $13-15. This marks the fourth-largest US biotech IPO ever, coming in behind Genentech ($1.9bn), Catalent Pharma ($952mm), and Talecris (now part of Grifols; $550mm).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies